An observational study in Osteoporosis, Postmenopausal, sponsored by 424 General Military Hospital. Recruiting at 8 sites in 2 countries. Open to female participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by 424 General Military Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Osteoporosis, Postmenopausal with a site in Greece — 2 open to participants now, 3 under way, none of them phase 3. Osteoporosis, Postmenopausal · Greece.
Among the 14 studies in Osteoporosis, Postmenopausal with a site in Greece, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 13th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →2 of the 14 studies in Osteoporosis, Postmenopausal with a site in Greece are open now. Recruiting first, the newest first:
National and Kapodistrian University of Athens · Sites in Greece
Women only
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 50 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 150 is close to the median of 160 across 57 observational studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 91 across the 7 interventional studies, 150 across the 7 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 7 most frequent:
424 General Military Hospital is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
424 General Military Hospital has 4 studies filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
2 of the studies in Osteoporosis, Postmenopausal with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06164795424 General Military HospitalSequential Therapies After Osteoanabolic Treatment | 2027-06-01 |
| NCT05575167424 General Military HospitalSingle or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study) | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Osteoporosis, Postmenopausal with a site in Greece, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolics
Caucasian women with severe postmenopausal osteoporosis who have completed their course with romosozumab or a PTH analog will be assigned to one of the following 3 options: i) zoledronate 5mg infusion or ii) denosumab subcutaneous injections or iii) teriparatide or abaloparatide (for those previously treated with romosozumab) or romosozumab (for those previously treated with teriparatide or abaloparatide).
Endpoints: Primary: BMD changes at the lumbar spine at 12 months. Secondary: i) BMD changes at the non-dominant femoral neck and total hip at 12 and 24 months; ii) changes at levels of bone turnover markers throughout the study; iii) incident fractures: vertebral (clinical and morphometric identified on VFA scans) and non-vertebral
Postmenopausal women treated with severe osteoporosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal women treated with romosozumab for 12 months will receive a single zoledronate infusion (5mg) at 1 month after the last romosozumab dose
Drug: Zoledronate
Postmenopausal women treated with romosozumab for 12 months will receive subcutaneous denosumab injections (60mg) bi-annually for 12 months starting at 1 month after the last romosozumab dose
Drug: Denosumab
Postmenopausal women treated with romosozumab for 12 months will receive daily injections of teriparatide 20μg or abaloparatide 80μg for 12 months starting at 1 month after the last romosozumab dose
Drug: Teriparatide · Drug: Abaloparatide Injection (80 mcg)
Postmenopausal women treated with teriparatide for 24 months or abaloparatide for 18 monthswill receive a single zoledronate infusion (5mg) at 1 month after the last romosozumab dose
Drug: Zoledronate
Postmenopausal women treated with teriparatide for 24 months or abaloparatide for 18 months will receive subcutaneous denosumab injections (60mg) bi-annually for 12 months
Drug: Denosumab
Postmenopausal women treated with teriparatide for 24 months or abaloparatide for 18 months will receive month injections of romosozumab for 12 months
Drug: Romosozumab
intravenous infusion
Also known as: zoledronic acid; zolendronate
subcutaneous injection
Also known as: Dmab
subcutaneous injection
Also known as: TPTD
subcutaneous injection
Also known as: Romo
daily subcutaneous injection
lumbar spine bone mineral density
bone mineral density changes at the lumbar spine at 12 months measured by dual-energy absorptiometry (DXA)
Time frame: baseline to 12 months
femoral neck bone mineral density
bone mineral density changes at the femoral neck at 12 months measured by dual-energy absorptiometry (DXA)
Time frame: baseline to 12 months
total hip bone mineral density
bone mineral density changes at the total hip at 12 months measured by dual-energy absorptiometry (DXA)
Time frame: baseline to 12 months
P1NP
bone turnover (formation) marker
Time frame: baseline, 3 months, 6 months, 12 months
CTx
bone turnover (resorption) marker
Time frame: baseline, 3 months, 6 months, 12 months
Fractures
incident fractures: vertebral (clinical and morphometric identified on VFA scans) and non-vertebral
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Jun 2027, 42 months after the start.
Of 23 observational studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 65. This study's planned 42 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osteoporosis, Postmenopausal →
424 General Military Hospital